|drug2271||SivoMixx (200 billion) Wiki||0.71|
There is one clinical trial.
In light of its high morbidity and mortality, COronaVIrus Disease 19 (COVID-19) pandemic spread is considered an unprecedented global health challenge. Given the very limited therapeutic options available against Severe Acute Respiratory Syndrome - CoronaVirus-2 (SARS-CoV-2) epidemic at this time, the evaluation of new resources, designed in the first instance for other pathologies but potentially active against COVID-19, represents a priority in clinical research. This is an observational, retrospective, non-profit study on the adjuvant use of bacteriotherapy in the early control of disease progression in patients affected by COVID-19 and treated with the current standard of care on the basis of the interim guidelines of the Italian Society of Infectious and Tropical Diseases. The main purpose of the study is to evaluate the effectiveness of bacteriotherapy in reducing the clinical impact of acute diarrhea, containing the progression of COVID-19 and preventing the need for hospitalization in intensive care units.
Description: Comparison between the two groups. Acute diarrhea was defined as a stool with increased water content, volume, or frequency that lasts less than 14 days.Measure: delta of time of disappearance of acute diarrhea Time: 21 days
Description: Comparison between the two groupsMeasure: Delta in the number of patients requiring orotracheal intubation despite treatment Time: 21 days
Description: Comparison between the two groupsMeasure: Delta of crude mortality Time: 21 days
Description: Comparison between the two groupsMeasure: Delta of length of stay for patients in hospital Time: 21 days